The estimated Net Worth of William Garrett Gray is at least $2.42 Million dollars as of 26 June 2024. Mr. Gray owns over 13,038 units of Checkpoint Therapeutics Inc stock worth over $1,485,531 and over the last 7 years he sold CKPT stock worth over $396,081. In addition, he makes $542,348 as Vice President - Finance and Accounting, Principal Financial Officer und Corporate Secretary at Checkpoint Therapeutics Inc.
Sign up
Mr. Gray CKPT stock SEC Form 4 insiders trading
William has made over 11 trades of the Checkpoint Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 13,038 units of CKPT stock worth $26,858 on 26 June 2024.
The largest trade he's ever made was selling 38,197 units of Checkpoint Therapeutics Inc stock on 10 March 2022 worth over $72,192. On average, William trades about 8,870 units every 88 days since 2018. As of 26 June 2024 he still owns at least 672,186 units of Checkpoint Therapeutics Inc stock.
You can see the complete history of Mr. Gray stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Gray biography
William Garrett Gray serves as Vice President - Finance and Accounting, Principal Financial Officer, Corporate Secretary of the Company. Mr. Gray has served as our Vice President, Finance and Accounting since February 2016, as our Principal Financial Officer since December 2016, and as our Corporate Secretary since January 2018. Mr. Gray joined us from Keryx Biopharmaceuticals, Inc., a publicly traded biotechnology company, which he joined in 2013, and where he most recently served as Corporate Controller, helping grow the finance and accounting department during Keryx’s transition from a development-stage company to a fully integrated commercial organization. Prior to joining Keryx, Mr. Gray began his professional career with Deloitte & Touche, LLP, where he served as a senior auditor. Mr. Gray has a Bachelor of Science degree in Accounting from Lehigh University and is a Certified Public Accountant in the State of New York.
What is the salary of William Gray?
As the Vice President - Finance and Accounting, Principal Financial Officer und Corporate Secretary of Checkpoint Therapeutics Inc, the total compensation of William Gray at Checkpoint Therapeutics Inc is $542,348. There are 2 executives at Checkpoint Therapeutics Inc getting paid more, with James Oliviero having the highest compensation of $2,308,250.
How old is William Gray?
William Gray is 32, he's been the Vice President - Finance and Accounting, Principal Financial Officer und Corporate Secretary of Checkpoint Therapeutics Inc since 2018. There are 9 older and no younger executives at Checkpoint Therapeutics Inc. The oldest executive at Checkpoint Therapeutics Inc is Lindsay Rosenwald, 65, who is the Director.
What's William Gray's mailing address?
William's mailing address filed with the SEC is 95 SAWYER RD, SUITE 110, , WALTHAM, MA, 02453.
Insiders trading at Checkpoint Therapeutics Inc
Over the last 8 years, insiders at Checkpoint Therapeutics Inc have traded over $1,535,168 worth of Checkpoint Therapeutics Inc stock and bought 200,000 units worth $356,000 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss und James F Iii Oliviero. On average, Checkpoint Therapeutics Inc executives and independent directors trade stock every 94 days with the average trade being worth of $93,898. The most recent stock trade was executed by James F Iii Oliviero on 26 June 2024, trading 24,610 units of CKPT stock currently worth $50,451.
What does Checkpoint Therapeutics Inc do?
checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr
What does Checkpoint Therapeutics Inc's logo look like?
Complete history of Mr. Gray stock trades at Checkpoint Therapeutics Inc
Checkpoint Therapeutics Inc executives and stock owners
Checkpoint Therapeutics Inc executives and other stock owners filed with the SEC include:
-
James Oliviero,
President, Chief Executive Officer, Director -
James F. Oliviero III, C.F.A., CFA,
Pres, CEO & Director -
William Gray,
Vice President - Finance and Accounting, Principal Financial Officer, Corporate Secretary -
William Garrett Gray,
CFO, Corp. Sec. & Treasurer -
Neil Herskowitz,
Independent Director -
Michael Weiss,
Chairman of the Board -
Barry Salzman,
Independent Director -
Scott Boilen,
Independent Director -
Christian Bechon,
Independent Director -
Lindsay Rosenwald,
Director -
Biotech, Inc. Fortress,
10% owner -
Sharma Amit,
Director